Business
Champions Oncology Reports Record Annual Revenue of $57 Million
Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology
About this update from Champions Oncology, Inc.
[{"type":"text","content":"Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2025.Fourth Quarter Financial Highlights:Total revenue of $12.3 millionAdjusted EBITDA loss of $1.2 millionNew data licensing revenue of approximately $200,000Operating cash flow of $6.4 millionFiscal Year 2025 Financial Highlights:Record annual revenue of $57 million, an increase of 14% year-over-yearNet income of $4.6 millionAdjusted EBITDA income of $7.1 millionData license revenue of $4.7 millionYear-end cash balance of $9.8 millionRonnie Morris, CEO of Champions, commented, \"This past year was pivotal for the Company, as we returned to growth and profitability, launched a high-margin data business and laid the foundation for long-term value creation\". Added Morris, \"With a strong pipeline heading into fiscal 2026, we're confident in our ability to drive continued revenue growth and further accelerate the monetization of our data offering.\"David Miller, CFO of Champions added, \"Our financial turnaround in fiscal 2025 was driven by disciplined execution and operational efficiency. We delivered record adjusted EBITDA, and strengthened our balance sheet, all while investing in scalable growth. We believe we're well positioned to build on this momentum in fiscal 2026.\"Fourth Quarter Financial ResultsTotal oncology revenue for the fourth quarter of fiscal 2025 was $12.4 million, compared to $14.0 million for the same period last year, a decrease of 12%, but in line with expectations. Total costs and operating expenses for the fourth quarter of fiscal 2025 were $14.4 million compared to $14.2 million for the fourth quarter of fiscal 2024, a slight increase of $170,000 or 1%.For the fourth quarter of fiscal 2025, Champions reported a loss from operations of $2.0 million, which includes $131,000 in stock-based compensation, $394,000 in depreciation and amortization, and a $293,000 charge on the disposal of lab equipment, compared to a loss from operations of $190,000, inclusive of $263,000 in stock-based compensation, $457,000 in depreciation and amortization, and a $354,000 charge on the disposal of lab equipment in the fourth quarter of fiscal 2024. Exclu...